Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clini...( NATICK Mass. May 14 /- Boston Scienti...),Health

NATICK, Mass., May 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced data from its ALTITUDE Clinical Science program that show real-word survival rates for implantable cardiac device patients exceeding rates from clinical trials. ALTITUDE analyzes outcomes data from patients monitored by the LATITUDE(R) Patient Management system. Five-year survival rate data for patients using implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) were presented at the Heart Rhythm Society Scientific Sessions in Boston by Leslie Saxon, M.D., F.A.C.C., Chief, Cardiovascular Medicine at the Cardiovascular and Thoracic Institute, University of Southern California, and chairperson of the ALTITUDE physician panel.

Boston Scientific has enrolled more than 130,000 patients on the LATITUDE system since its introduction in 2006, making it the most rapidly adopted remote cardiac device monitoring system in the industry(1). The LATITUDE system enables physicians to schedule remote follow-ups of implantable cardiac device patients to monitor specific device information and heart health status. The system can also detect clinical events between scheduled visits and send relevant data directly to physicians. This regular, in-home monitoring offers convenience and peace of mind for patients.

Findings presented today from ALTITUDE, which analyzed nearly 86,000 patients monitored by the LATITUDE system, include:

• Five-year survival rates for ICD patients of up to 92 percent
• Five-year survival rates for CRT-D patients of up to 78 percent

"In contrast to clinical trials, the ALTITUDE program analyzes device therapy in real-world practice and offers insights into
'/>"/>